OUR MISSION
Our mission is to help pets live longer, healthier, and happier lives
Our four-legged family members are living longer than ever, bringing us much joy.
Unfortunately, with this longer life span, our furry friends are now suffering from more cancers and other diseases of chronic inflammation — just like us. 
OUR LEAD PRODUCT
ElenaVet® is a gene therapy that enhances the body's anticancer immune response.
In our comparative medicine studies, we saved 10 out of 11 dogs with breast cancer and precluded or delayed the metastatic process in dogs with melanoma. We observed similar results with cats. Read more
ElenaVet also reduces chronic inflammation, which causes not only cancer but other serious diseases such as osteoarthritis, Inflammatory bowel disease (IBD), and chronic dermatologic issues — as well as age-associated declines. Our goal is to tackle these diseases one by one, starting with cancer.
Less
OUR LEAD PRODUCT
ElenaVet® is a gene therapy that enhances the body's anticancer immune response.
In our comparative medicine studies, we saved 10 out of 11 dogs with breast cancer and precluded or delayed the metastatic process in dogs with melanoma. We observed similar results with cats. Read more
ElenaVet also reduces chronic inflammation, which causes not only cancer but other serious diseases such as osteoarthritis, Inflammatory bowel disease (IBD), and chronic dermatologic issues — as well as age-associated declines. Our goal is to tackle these diseases one by one, starting with cancer.
Less
PATIENT TESTIMONY
If your pet is suffering from breast cancer, oral melanoma, osteoarthritis or IBD, we may be able to help you right away - free of charge - by partnering with your veterinarian.
Sign up here to receive updates about our breakthrough
pet cancer therapy
Sign up here to receive updates about our breakthrough
pet cancer therapy
OUR STORY
A biotech startup - with an established track record.
CureLab Veterinary, a sister company of CureLab Oncology, was created in November 2020 to save lives and improve the welfare of cats, dogs, and horses.
Read more
Our parent company, which is focused solely on human immune-oncology, was established in 2012 by experienced scientists and business experts. Our advisory board includes a Nobel Laureate and a recent member of the US president’s cabinet. Our work on readying our therapy for human clinical trials has shown that our product is safe and effective in dogs and cats.
Less
CANCER
How does ElenaVet work?
Why does your pet have a cancer?
Both pets and humans have pre-cancer and even cancer cells, but these bad cells can do no harm unless the tissue surrounding them allows the formation of primary tumors and the potential for metastasis.Read more
Often, pre-cancer cells can form tumors when a surrounding tissue is in a state of chronic inflammation. Additionally, tumors use chronic inflammation within the tumor to suppress the body’s natural anticancer immune response to resist treatments. Administering ElenaVet reduces chronic inflammation. This means it has excellent anti-cancer potency and synergizes well with other anti-cancer therapies.
Less
A tumor is not a bag full of cancer cells. Cancer cells cannot survive without the support of tumor stroma cells. ElenaVet alters tumor stroma making it less supportive for cancer cells. For example, a tumor prognosis is correlated with an expression of a protein called α-SMA. Our product reduced the tumor risk modulating α-SMA ‘s expression level.
CANCER
How does ElenaVet work?
Why does your pet have a cancer?
Both pets and humans have pre-cancer and even cancer cells, but these bad cells can do no harm unless the tissue surrounding them allows the formation of primary tumors and the potential for metastasis.Read more
Often, pre-cancer cells can form tumors when a surrounding tissue is in a state of chronic inflammation. Additionally, tumors use chronic inflammation within the tumor to suppress the body’s natural anticancer immune response to resist treatments. Administering ElenaVet reduces chronic inflammation. This means it has excellent anti-cancer potency and synergizes well with other anti-cancer therapies.
Less
ELENAVET
How does ElenaVet work?
• ElenaVet corrects the tumor microenvironment surrounding cancer cells, making it more favorable for anti-cancer immunity.• ElenaVet changes the tumor structure itself, making it harder for metastatic cells to exit the tumor and form new remote lesions.
Read more
The grade of a tumor — the cancer grade — is an indication of how quickly it is likely to grow and spread. Tumors of higher grades are more resistant to treatments. Our ElenaVet prototype reverted/reduced the tumor grade in five out of six canine mammary cancers; and in one case out of six, the tumor was reverted to a non-cancerous state.
Less
The extracellular matrix in a tumor is predominantly formed of collagen Type 1. Treatment with ElenaVet shifts it from Type 1 to Type 3. This shift in collagen type is important as Lymphocytes circulating in the blood use collagen Type 3 more efficiently to penetrate the tumor and attack it. Metastatic cells have a harder time exiting the tumor if collagen Type 3 is present...
ELENAVET
How does ElenaVet work?
• ElenaVet corrects the tumor microenvironment surrounding cancer cells, making it more favorable for anti-cancer immunity.• ElenaVet changes the tumor structure itself, making it harder for metastatic cells to exit the tumor and form new remote lesions.
Read more
The grade of a tumor — the cancer grade — is an indication of how quickly it is likely to grow and spread. Tumors of higher grades are more resistant to treatments. Our ElenaVet prototype reverted/reduced the tumor grade in five out of six canine mammary cancers; and in one case out of six, the tumor was reverted to a non-cancerous state.
Less
ELENAVET
Non-cancer diseases
What do osteoarthritis, inflammatory bowel disease, chronic dermatologic issues, and age-associated declines have in common? All of them are diseases of chronic inflammation.ElenaVet reduces chronic inflammation in the most comprehensive way. It lowers pro-inflammatory cytokines and increases anti-inflammatory ones, thereby dramatically reducing overall inflammation.
Read more
What happens when you cut your finger or catch a cold?
Cells and tissues “scream for help” — sending out pro-inflammatory cytokines. When the danger is over, anti-inflammatory cytokines calm the tissue down.
And what if the body doesn’t check the pro-inflammation process?
Then we have a constant release of pro-inflammatory cytokines, causing chronic inflammation.
What’s wrong with current anti-inflammatory treatments?
They either target one specific proinflammatory cytokine or are highly toxic.
ElanaVet has neither of these drawbacks.
Less
Instead of interfering with a particular cytokine, ElenaVet restores balance in the cells secreting them.
ELENAVET
What is ElenaVet?
ElenaVet is a plasmid (supercoiled circular DNA) in which we have inserted a gene-encoding protein p62/SQSTM1. Plasmids constitute a main trend in a new generation of biomedicine.
When injected into a patient, ElenaVet enters cells at the site of administering as well as in the bone marrow, and makes the cells it encodes produce p62 protein, which leads to multiple physiological outcomes.
Read more
Plasmids manufacturing is now efficient and highly scalable allowing for a price that is accessible to the general public which will result in helping tens of thousands of animals. If kept frozen, their shelf life is more than six years. Their regulatory approval process is straightforward. And the current dosage form is a simple intramuscular injections.
Less
Manufacturing is outsourced to a leading contract manufacturing partner experienced with USDA and FDA regulations.
ELENAVET
From laboratory to your veterinary clinics
Partnering
If you are an academic or private veterinary clinic, be among the leaders joining our clinical research programs for the latest therapy against cancer, osteoarthritis and inflammatory bowel disease. Your patient deserves to be included in the latest, cutting-edge study.Today, you can join our comparative medicine studies for breast cancer, melanoma, osteoarthritis, inflammatory bowel disease, chronic dermatitis and anti-aging.
Please contact us:
We will provide you with the product and we will publish the results together.
ELENAVET
From laboratory to your veterinary clinics
Partnering
If you are an academic or private veterinary clinic, be among the leaders joining our clinical research programs for the latest therapy against cancer, osteoarthritis and inflammatory bowel disease. Your patient deserves to be included in the latest, cutting-edge study.Today, you can join our comparative medicine studies for breast cancer, melanoma, osteoarthritis, inflammatory bowel disease, chronic dermatitis and anti-aging.
Please contact us:
We will provide you with the product and we will publish the results together.
ELENAVET
Regulatory
We will pursue a regulatory approval through the USDA, which will be much faster and less costly than through the FDA.Read more
Official USDA-controlled studies of application of ElenaVet to canine breast cancer, melanoma and feline breast cancer are expected to begin in 2021. Anticipated conditional licensure within 24 months. The company has secured assistance of an experienced regulatory group formed by former USDA specialists.
Less
ELENAVET
Regulatory
We will pursue a regulatory approval through the USDA, which will be much faster and less costly than through the FDA.Read more
Official USDA-controlled studies of application of ElenaVet to canine breast cancer, melanoma and feline breast cancer are expected to begin in 2021.
Anticipated conditional licensure within 24 months.
The company has secured assistance of an experienced regulatory group formed by former USDA specialists.
Less
TEAM
Management
Alexander Shneider, Ph.D.
Founder, Chairman of the Board, Interim CEO
Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for the journals Aging and Cell Cycle; advisor at We Fund Health. Achievements and activities include drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
Robert Devlin, DVM, MBA
Executive Consultant
Rob progressed from a practicing veterinarian to an executive director of veterinary science division to a seasoned VP of business development. Proven US and international track record in operations management, online and multichannel B2B and B2C sales within the animal health market, working with and developing US CMO vendors as well as distribution channels, spokespeople, and market KOLs, and establishing pricing models.
Jason Payne, MBA (finance)
CFO
Progressing from a financial analyst to a CFO, Jason acquired comprehensive experience including planning and directing execution of day-to-day accounting and financial management initiatives (financial planning, forecasting, budgeting, variance analysis, fundraising, and KPI setting/achievement tracking aimed at eliminating risks and reducing costs), preparing reports for recording of assets, liabilities, P&L, corporate tax filing.
Vlad Gabai, Ph.D.
VP of R&D
Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.Read more
Franco Venanzi, Ph.D.
Director of Basic Research
Over 30 years of biomedical research, over 20 years of tenured faculty professorship at University of Camerino, Italy, where he was Head of the Translational Biology Laboratory; 20 years of service as editor-in-chief, editorial board member and a reviewer for vaccination and immunobiology journals.
Stephen Spector
VP of Strategic BD
Steve past experience includes online B2B & B2C marketing & sales of Techmira Corp., marketing patented teeth-cleaning products for pets and pain-reducing anti-inflammatory devices.
Tim Cox
PR consultant
25 years of successful PR and brand-building experience for technology and biotech companies. Defined and executed the PR campaign for the launch of Embrace Pet Insurance. Formerly brand marketing at Apple.
Ilya Lapshin
JD – Legal Counsel
18 years of legal experience in a large New York law firm and two Massachusetts-based boutique firms helping startups and big corporate clients. Between a double major at MIT, physics withLess
TEAM
Advisory Board
B. Duncan X. Lascelles
BSc, BVSC, PhD, FRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS
NC State University, College of Veterinary VedicineProfessor of Surgery and Pain Management
Director, Translational Research in Pain [TRiP] Program
Director, Comparative Pain Research and Education Center
Jörg M. Steiner
Med.vet., Dr.med.vet., PhD, DACVIM-SAIM, DECVIM-CA, AGAF
Texas A&M College of Veterinary Medicine & Biomedical Sciences University Distinguished ProfessorSmall Animal Internal Medicine
Dr. Mark Morris Chair in Small Animal Gastroenterology and Nutrition
Director, Gastrointestinal Laboratory
Zachary M. Wright
DVM DACVIM (oncology)
Chair of the VCA Pet CancerCare AllianceMedical Director-VCA Animal Diagnostic Clinic
Keith Richter
DVM, DACVIM
Previously a Professor at the Cornell University College of VeterinaryMedicine, Hospital Director of the Veterinary Specialty Hospital, Chief
Medical Office of Ethos Veterinary Health, President and Board of Regents
Member of the Comparative Gastroenterology Society, Board of Regents
Member of American College of Veterinary Internal Medicine.
Ross H. Palmer
DVM, MS, DACVS
Colorado State UniversityVeterinary Medical Center
Department Of Clinical Sciences
Professor
Associate Director Of Education at Translational Medicine
TEAM
Advisory Board
B. Duncan X. Lascelles
BSc, BVSC, PhD, FRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS
NC State University, College of Veterinary VedicineProfessor of Surgery and Pain Management
Director, Translational Research in Pain [TRiP] Program
Director, Comparative Pain Research and Education Center
Jörg M. Steiner
Med.vet., Dr.med.vet., PhD, DACVIM-SAIM, DECVIM-CA, AGAF
Texas A&M College of Veterinary Medicine & Biomedical Sciences University Distinguished ProfessorSmall Animal Internal Medicine
Dr. Mark Morris Chair in Small Animal Gastroenterology and Nutrition
Director, Gastrointestinal Laboratory
Zachary M. Wright
DVM DACVIM (oncology)
Chair of the VCA Pet CancerCare AllianceMedical Director-VCA Animal Diagnostic Clinic
Keith Richter
DVM, DACVIM
Previously a Professor at the Cornell University College of VeterinaryMedicine, Hospital Director of the Veterinary Specialty Hospital, Chief
Medical Office of Ethos Veterinary Health, President and Board of Regents
Member of the Comparative Gastroenterology Society, Board of Regents
Member of American College of Veterinary Internal Medicine.
Ross H. Palmer
DVM, MS, DACVS
Colorado State UniversityVeterinary Medical Center
Department Of Clinical Sciences
Professor
Associate Director Of Education at Translational Medicine
INVESTORS
Download our One-Pager investor prospectus
INVESTORS
Market size
FAST FACTS
Almost 90 million dogs in the USA, 85 million in Europe — and the number is growing.
Cancer is now the #1 cause of death for dogs.
FAST FACTS
Almost 96 million in US, 103 million in Europe — and the number is growing.
90% of cats over 12 years have osteoarthritis.
FAST FACTS
Almost 96 million in US, 103 million in Europe — and the number is growing.
90% of cats over 12 years have osteoarthritis.
FAST FACTS
Anticipated cost per a course of treatment
$ 1.5-3K
Anticipated profit per a course of treatment
$ 0.5-1K
$ 0.5-1K
FAST FACTS
The global animal health market size by 2028
USD 74.5 billion
CAGR of 5.9%
Traditional cancer care in dogs:
• $ 150-600 per dose of chemotherapy• $ 1,000-6,000 for a radiation protocol
FAST FACTS
The global animal health market size by 2028
USD 74.5 billion
CAGR of 5.9%
Traditional cancer care in dogs:
• $ 150-600 per dose of chemotherapy• $ 1,000-6,000 for a radiation protocol
IP
CureLab
Oncology Inc.
has granted to its sister company CureLab Veterinary Inc.
an exclusive worldwide license
for application of its existing
and future IP to cats, dogs, and horses.
Oncology patents
Read more
Patent Granted
Australia
Chile
Russia
Belarus
Belgium
Switzerland
Lichtenstein
Germany
Spain
France
UK
Ireland
Italy
Luxembourg
Netherlands
Hong Kong
Japan
South Korea
Mexico
Singapore
USA
India
Patent Application Pending
Canada
USA
Brazil
Less
Anti-inflammation patents
Read more
Patent Granted
Australia
Hong Kong
Japan
Singapore
Belgium
Switzerland
Lichtenstein
Germany
France
UK
Luxembourg
Monaco
Netherlands
Japan
South Korea
Mexico
Singapore
USA
Patent Application Pending
Canada
China
India
USA
Italy
Spain
Less
IP
CureLab
Oncology Inc.
has granted to its sister company CureLab Veterinary Inc.
an exclusive worldwide license
for application of its existing
and future IP to cats, dogs, and horses.
Oncology patents
Read more
Patent Granted
Australia
Chile
Russia
Belarus
Belgium
Switzerland
Lichtenstein
Germany
Spain
France
UK
Ireland
Italy
Luxembourg
Netherlands
Hong Kong
Japan
South Korea
Mexico
Singapore
USA
India
Patent Application Pending
Canada
USA
Brazil
Less
Anti-inflammation patents
Read more
Patent Granted
Australia
Hong Kong
Japan
Singapore
Belgium
Switzerland
Lichtenstein
Germany
France
UK
Luxembourg
Monaco
Netherlands
Japan
South Korea
Mexico
Singapore
USA
Patent Application Pending
Canada
China
India
USA
Italy
Spain
Less
PUBLICATION
We publish our results
in top peer-reviewed journals
Read more about the science that underpins our therapy in leading scientific publications.
- P62-DNA-encoding plasmid reverts tumor grade, changes tumor stroma, and enhances anticancer immunity
- Pilot study of p62 DNA vaccine in dogs with mammary tumors
- P62/SQSTM1 beyond Autophagy: Physiological Role and Therapeutic Applications in Laboratory and Domestic Animals
- p62 / SQSTM1 expression in canine mammary tumors: evolutionary notes
- Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector
- P62/SQSTM1 enhances osteogenesis and attenuates inflammatory signals in bone marrow microenvironment
- Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent
- P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions
- p62 /SQSTM1 coding plasmid prevents age-related macular degeneration in a rat model
- Neuroprotective effects of p62 (SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study
- Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
- Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy
Less
CONTACT US
177 HUNTINGTON
AVE FL 17
BOSTON MA
02115-3156
CONTACT US
AVE FL 17
BOSTON MA
02115-3156